FindTrial
Sign In

Fifth population based covid19 Antibody study in Ahmedabad.

Fifth population based serosurveillance for SARS-CoV2 using IgG antibodies in Ahmedabad - AB5

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/05/033845
Enrollment
4500
Registered
2021-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Ahmedabad Municipal Corporation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Those who give informed written consent

Exclusion criteria

Exclusion criteria: any bleeding disorder, contraindication to venipuncture & hospitalized patients

Design outcomes

Primary

MeasureTime frame
Seroprevalence of IgG Antibodies against SARS-CoV-2 in general population of AhmedabadTimepoint: 1. Since this is a cross sectional study, there is only one time point—

Secondary

MeasureTime frame
Factors affecting antibody based immunity against SARS-CoV2 infectionTimepoint: 1. Since this is a cross sectional study, there is only one time point—

Countries

India

Contacts

Public ContactDr Om Prakash

Ahmedabad Municipal Corporation

dromprakash2006@gmail.com9099012740

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026